A study of therapy-related acute leukaemia after mitoxantrone therapy for multiple sclerosis

Multiple Sclerosis

Volumn 8, Issue 5, 2002, Pages 441-445

  Ghalie, R G ^a   Mauch, E ^b   Edan, G ^c   Hartung, H P ^d   Gonsette, R E ^e   Eisenmann, S ^b   Le Page, E ^c   Butine, M D ^a   Goodkin, D E ^a  

^a AMGEN INC   (United States)

^b Clinic for Neurological Diseases   (Germany)

^c PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

^d UNIVERSITY OF GRAZ   (Austria)

^e Centre National de la Sclerose en Plaques   (Belgium)

Author keywords

Leukaemia; Mitoxantrone; Multiple sclerosis; Myelodysplastic syndrome

Indexed keywords

GYRASE INHIBITOR; IDARUBICIN; METHYLPREDNISOLONE; MITOXANTRONE; RETINOIC ACID;

ACUTE LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD TOXICITY; CHRONICITY; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE CALCULATION; DRUG MEGADOSE; DRUG TOLERABILITY; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEDICAL LITERATURE; MEDICAL RECORD; MONOTHERAPY; MULTIPLE SCLEROSIS; MYELODYSPLASTIC SYNDROME; PHASE 3 CLINICAL TRIAL; PROMYELOCYTIC LEUKEMIA; RANDOMIZED CONTROLLED TRIAL; RISK; SOLID TUMOR;

ACUTE DISEASE; ADOLESCENT; ADULT; AGED; CLINICAL TRIALS, PHASE III; FEMALE; FRANCE; GERMANY; HUMANS; INCIDENCE; LEUKEMIA; MALE; MEDICAL RECORDS; MIDDLE AGED; MITOXANTRONE; MULTICENTER STUDIES; MULTIPLE SCLEROSIS; RANDOMIZED CONTROLLED TRIALS; RETROSPECTIVE STUDIES;

EID: 0036783808     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1191/1352458502ms836oa     Document Type: Article

References (34)

1. Leukaemia in breast cancer patients following adjuvant chemotherapy or postoperative radiation: The NSABP experience
2. Risk of leukaemia after chemotherapy and radiation treatment for breast cancer
3. Second malignancies following CMF-based adjuvant chemotherapy in resectable breast cancer
4. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease
5. Risk of cancer from azathioprine therapy in multiple sclerosis: A case-control study
6. Risk of developing certain malignancies is related to duration of immunosuppressive drug exposure in patients with rheumatic diseases
7. The incidence of tumours in renal transplant recipients with long-term immunosuppressive therapy
8. Secondary leukaemias induced by topoisomerase-targeted drugs
9. Second cancers
10. Balanced chromosome aberrations in leukaemias following chemotherapy with DNA-topoisomerase II inhibitors
11. Mitoxantrone in progressive multiple sclerosis: A placebo-controlled, randomised, observer-blind phase III trial: Clinical results and three-year follow-up
12. Safety profile of mitoxantrone in a cohort of 293 multiple sclerosis patients
13. Mitoxantrone in the treatment of patients with multiple sclerosis (MS): A large single-center experience
14. An open-trial evaluation of mitoxantrone in the treatment of progressive MS
15. Randomised placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-Month clinical and MRI outcome
16. Mitoxantrone in the treatment of rapidly progressive multiple sclerosis: A pilot study with serial gadolinium-enhanced MRI
17. Treatment of multiple sclerosis with mitoxantrone. 14th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
18. Mitoxantrone therapy of secondary progressive multiple sclerosis: Pilot study
19. Mitoxantrone immunotherapy in multiple sclerosis
20. Results of an open study with 74 MS patients treated with mitoxantrone. 14th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
21. Clinical outcome of mitoxantrone (MTX) treatment in secondary-progressive multiple sclerosis (SPMS) patients
22. Safety and tolerability of mitoxantrone in patients with multiple sclerosis
23. Acute promyelocytic leukaemia following mitoxantrone as single agent for the treatment of multiple sclerosis
24. Epidemiology
25. High risk of therapy-related leukaemia and preleukaemia after therapy with prednimustine, methotrexate, 5-fluorouracil, mitoxantrone, and tamoxifen for advanced breast cancer
26. Secondary myelodysplastic syndrome/acute myeloid leukaemia following mitoxantrone-based therapy for breast carcinoma
27. Increased risk of acute leukaemia after adjuvant chemotherapy for breast cancer: A population-based study
28. Intensification of adjuvant chemotherapy: 5-year results of a randomized trial comparing conventional doxorubicin and cyclophosphamide with high-dose mitoxantrone and cyclophosphamide with filgrastim in operable breast cancer with 10 or more involved axillary nodes
29. Early secondary acute myelogenous leukaemia in breast cancer patients after treatment with mitoxantrone, cyclophosphamide, fluorouracil and radiation therapy
30. Cancer risk after adjuvant chemo- or chemohormonal therapy of breast cancer
31. Myelodysplasia and acute myeloid leukaemia following adjuvant chemotherapy for breast cancer using mitoxantrone and methotrexate with or without mitomycin
32. Registry to evaluate Novantrone effects in worsening MS (The RENEW Study): A work in progress